Caribou Biosciences signals access challenge in CAR-T cell therapy

Caribou Biosciences signals access challenge in CAR-T cell therapy
@CaribouBio: Caribou warns on CAR-T access

Caribou Biosciences has raised concerns about the accessibility of CAR-T cell therapy for patients living significant distances from treatment centers. According to recent findings, patients residing 2–4 hours away are 40 percent less likely to receive the therapy.

This accessibility issue will be a focal point of discussion at the upcoming ASH Annual Meeting. Leading community and academic clinicians will explore potential solutions to this critical problem.

These challenges in patient accessibility are intricately linked to broader logistical considerations in delivering CAR-T therapies. Recent developments in CAR-T supply chain strategies, as detailed in Caribou Biosciences' unveiling of new data on CAR-T supply chain strategies, underscore the importance of coordinated efforts across the industry to ensure therapies reach patients regardless of geography.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.